title: Enhancing the hepatic protective effect of genistein by oral administration with stachyose in mice with chronic high fructose diet consumption.
abstract: Dietary supplementation of soy stachyose or genistein is known to be of hepatoprotective health interest. This study showed that co-administration of genistein and stachyose caused stronger inhibition on abnormal weight gain and liver fat accumulation by decreasing fatty acid synthetase expression and balancing disorderly lipid metabolism than that of genistein or stachyose alone in high-fructose (HF) diet-fed mice. Furthermore, the production of malonaldehyde and carbonyl derivatives of proteins was also more effectively inhibited by co-treatment of genistein and stachyose, and thereby glutathione peroxidase and superoxide dismutase activities were elevated in HF-fed mice. Moreover, genistein in combination with stachyose was more effective to reduce the impact of HF on the serum markers of liver damage by inhibiting inflammatory cytokine release than stachyose or genistein alone in mice. The potential mechanism was that stachyose enhanced absorption of genistein in HF-fed mice by oral supplementation of genistein together with stachyose. These findings indicate that co-ingestion of stachyose and genistein may serve as a novel strategy for hepatic protection.
authors.affiliation: Shaanxi Engineering Laboratory for Food Green Processing and Safety Control, College of Food Engineering and Nutritional Science, Shaanxi Normal University, Xi'an 710062, China. lizhao0309@snnu.edu.cn xbyang@snnu.edu.cn.
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Li
authors.forename: Zhao
authors.initials: Z
authors.lastname: Li
authors.forename: Xiao
authors.initials: X
authors.lastname: Han
authors.forename: Di
authors.initials: D
authors.lastname: Huang
authors.forename: Yalong
authors.initials: Y
authors.lastname: Lu
authors.forename: Xingbin
authors.initials: X
authors.lastname: Yang
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D000284:Administration, Oral; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001774:Blood Chemical Analysis; D001835:Body Weight / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism; D004040:Dietary Carbohydrates / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D054889:Fatty Acid Synthase, Type II / Q000096:biosynthesis / Q000187:drug effects; D005227:Fatty Acids / Q000097:blood; D005234:Fatty Liver / Q000517:prevention & control; D005243:Feces / Q000737:chemistry; D005632:Fructose / Q000009:adverse effects*; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology*; D005979:Glutathione Peroxidase / Q000187:drug effects; D006706:Homeostasis / Q000187:drug effects; D007249:Inflammation; D007333:Insulin Resistance; D007408:Intestinal Absorption / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000737:chemistry / Q000187:drug effects* / Q000293:injuries / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D009844:Oligosaccharides / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D013025:Glycine max / Q000737:chemistry; D013482:Superoxide Dismutase / Q000187:drug effects; D014556:Urine / Q000737:chemistry; D015430:Weight Gain / Q000187:drug effects
chemical_list: D015415:Biomarkers; D016207:Cytokines; D004040:Dietary Carbohydrates; D004338:Drug Combinations; D005227:Fatty Acids; D009844:Oligosaccharides; D020011:Protective Agents; C005695:stachyose; D005632:Fructose; D008315:Malondialdehyde; D019833:Genistein; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D054889:Fatty Acid Synthase, Type II